{"protocolSection":{"identificationModule":{"nctId":"NCT00216411","orgStudyIdInfo":{"id":"A-9B-52120-097"},"organization":{"fullName":"Ipsen","class":"INDUSTRY"},"briefTitle":"Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm","officialTitle":"A Prospective Phase IV, Multicentre, Placebo-controlled Study to Demonstrate Changes in the Quality of Life Following DYSPORT Intramuscular Injection in the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients"},"statusModule":{"statusVerifiedDate":"2019-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2004-11"},"primaryCompletionDateStruct":{"date":"2006-07-20","type":"ACTUAL"},"completionDateStruct":{"date":"2006-07-20","type":"ACTUAL"},"studyFirstSubmitDate":"2005-09-13","studyFirstSubmitQcDate":"2005-09-20","studyFirstPostDateStruct":{"date":"2005-09-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-07-25","lastUpdatePostDateStruct":{"date":"2019-07-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"Ipsen","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The main purpose of this study is to assess the effect on Quality of Life of two cycles of Dysport treatment on post-stroke spasticity of the upper limb. The effect of treatment on spasticity and function will also be measured."},"conditionsModule":{"conditions":["Cerebrovascular Accident","Muscle Spasticity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":96,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Dysport","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum toxin type A"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum toxin type A","armGroupLabels":["Dysport"],"otherNames":["AbobotulinumtoxinA (DysportÂ®)"]},{"type":"DRUG","name":"Placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in quality of life measured using the Assessment of Quality of Life questionnaire (12 question version)."}],"secondaryOutcomes":[{"measure":"Change in muscle spasticity assessed on Modified Ashworth Scale (MAS)"},{"measure":"Change in the Modified Motor Assessment Scale"},{"measure":"Change in patient disability and carer burden rating scale total score"},{"measure":"Achievement of the patient identified functional outcome measures (Goal Attainment Scaling)"},{"measure":"Change in the degree of pain"},{"measure":"Change in depression rating scale total score"},{"measure":"Global assessment of benefit"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient has suffered a stroke, as defined by the World Health Organisation (WHO) criteria, at least 6 months previously.\n* The patient has a hemiparetic arm and meets minimum score requirements on the Modified Ashworth Scale.\n* The patient has the cognitive and communication ability to participate in the study.\n\nExclusion Criteria:\n\n* Patients who have received botulinum toxin treatment within the past 120 days.\n* Contraindication to botulinum toxin treatment.\n* Patients who are receiving oral anti-spasticity medication and who have had a change in dosage of this medication in the month prior to study entry.\n* Patients who have previously been treated with phenol for their upper limb spasticity.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Ipsen Medical Director","affiliation":"Ipsen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"St Josephs Hospital","city":"Auburn","state":"New South Wales","zip":"2144","country":"Australia","geoPoint":{"lat":-33.85,"lon":151.03333}},{"facility":"Royal Prince Alfred Hospital","city":"Camperdown","state":"New South Wales","zip":"2050","country":"Australia","geoPoint":{"lat":-33.88965,"lon":151.17642}},{"facility":"Prince of Wales Hospital","city":"Randwick","state":"New South Wales","zip":"2031","country":"Australia","geoPoint":{"lat":-33.91439,"lon":151.24895}},{"facility":"Box Hill Hospital","city":"Box Hill","state":"Victoria","zip":"3128","country":"Australia","geoPoint":{"lat":-37.81887,"lon":145.12545}},{"facility":"Caulfield General Medical Centre","city":"Caulfield","state":"Victoria","zip":"3162","country":"Australia","geoPoint":{"lat":-37.88251,"lon":145.02288}},{"facility":"Austin Health","city":"Heidelberg","state":"Victoria","zip":"3084","country":"Australia","geoPoint":{"lat":-37.75,"lon":145.06667}}]},"referencesModule":{"references":[{"pmid":"20111849","type":"DERIVED","citation":"Turner-Stokes L, Baguley IJ, De Graaff S, Katrak P, Davies L, McCrory P, Hughes A. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebo-controlled randomized clinical trial. J Rehabil Med. 2010 Jan;42(1):81-9. doi: 10.2340/16501977-0474."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Cerebrovascular Accident","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T6034","name":"Quality of Life","asFound":"Quality of Life","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Baricitinib","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}